Report #2865222

Received Oct 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: NY
Recovered: Unknown
Vaccinated: Oct 8, 2025
Onset: Oct 8, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

got shot 1 of Shingrix on an unspecified date in October 2024 and shot 2 on 08-OCT-2025 today on the day of reporting; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in OCT-2024). On 08-OCT-2025, the patient received the 2nd dose of Shingrix. On 08-OCT-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: got shot 1 of Shingrix on an unspecified date in October 2024 and shot 2 on 08-OCT-2025 today on the day of reporting). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 08-OCT-2025 The patient self-reported this case for herself. The batch number was not provided, and unable to contact the reporter.